All In Biotech

Drug Trial Radar · NCT05907291

Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn)

A 12-week, Phase 2 Open-label, Sequential Dose Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 Treatment in Participants With Congenital Adrenal Hyperplasia (TouCAHn)

Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

38

Actual

Start

Jul 3, 2023

Primary completion

Aug 22, 2025

Study completion Aug 22, 2025

Sponsor

Lead sponsor
Crinetics Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Jun 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Phase 2, open-label, sequential dose cohort study is to evaluate the safety, efficacy, and pharmacokinetics (PK) of atumelnant (CRN04894) in participants with classic congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency.

Conditions

  • Congenital Adrenal Hyperplasia
  • Classic Congenital Adrenal Hyperplasia

Interventions

  • atumelnant (CRN04894)Drug

    Atumelnant is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) antagonist.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Morning (Before 11:00) Serum Androstenedione (A4) PM DosingTime frame: Baseline and Week 12
  2. Change From Baseline in Morning (Before 11:00) Serum Androstenedione (A4) AM DosingTime frame: Baseline and Week 12
  3. Number of Participants Reporting of Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, and Adverse Events Leading to Discontinuation Throughout the StudyTime frame: From Day 1 to Up to Week 16 (End of study)

Locations

27 sites in 7 countries. Site status is shown where the registry gives one.

  • Crinetics Study Site

    Pasadena, California

  • Crinetics Study Site

    Ann Arbor, Michigan

  • Crinetics Study Site

    Minneapolis, Minnesota

  • Crinetics Study Site

    St Louis, Missouri

  • Crinetics Study Site

    Morehead City, North Carolina

  • Crinetics Study Site

    Cleveland, Ohio

  • Crinetics Study Site

    Philadelphia, Pennsylvania

  • Crinetics Study Site

    East Providence, Rhode Island

  • Crinetics Study Site

    Buenos Aires, Argentina

  • Crinetics Study Site

    Córdoba, Córdoba Province, Argentina

  • Crinetics Study Site

    Rio de Janeiro, Brazil

  • Crinetics Study Site

    Rio de Janeiro, Brazil

  • Crinetics Study Site

    São Paulo, Brazil

  • Crinetics Study Site

    São Paulo, Brazil

  • Crinetics Study Site

    Curitiba, Paraná, Brazil

  • Crinetics Study Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • Crinetics Study Site

    Botucatu, São Paulo, Brazil

  • Crinetics Study Site

    Ribeirão Preto, São Paulo, Brazil

  • Crinetics Study Site

    Munich, Bavaria, Germany

  • Crinetics Study Site

    Bangalore, Karnataka, India

  • Crinetics Study Site

    Vellore, Tamil Nadu, India

  • Crinetics Study Site

    Naples, Italy

  • Crinetics Study Site

    Roma, Italy

  • Crinetics Study Site

    Rozzano, Italy

  • Crinetics Study Site

    London, United Kingdom

  • Crinetics Study Site

    Sheffield, South Yorkshire, United Kingdom

  • Crinetics Study Site

    Coventry, West Midlands, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.